Thanks Beacher for the update. What I find disapp
Post# of 22453
What I find disappointing is that we are not getting an S1 filing until MAYBE late Q4 2023. Even then, the company will most likely have $0 in revenues to capitalize on, as we will, if we're lucky, be in the middle of clinical trials for the multi test and just starting one for long Covid.
Why we are developing one for long Covid is beyond me. I feel as if that will be wasted time and money, imo.
Our counterfeiting and Q-Dot displays were my hopefuls, but that seems to have been placed in the hold bin unfortunately. And what about the tobacco trial? Did that not pan out?
They are betting everything on these two trials. Just so disappointing.